A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
Clinical trial NCT06103825 · COMPLETED
Trial details
- NCT number
- NCT06103825
- Sponsor
- Ignis Therapeutics (Suzhou) Limited
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-01
- Primary completion
- 2024-07-20
- Enrollment
- 204
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.